<DOC>
	<DOCNO>NCT00848276</DOCNO>
	<brief_summary>This study measure recently discover protein name PCSK9 ( Proprotein convertase subtilisin kexin 9 ) blood see influence male female sex hormone . PCSK9 recently show control cholesterol triglyceride level diminish ability liver cell remove cholesterol blood lead high blood cholesterol level . It find previous study relationship blood level PCSK9 cholesterol men woman . This gender difference new finding raise question whether male female hormone might influence PCSK9 's role blood cholesterol regulator . The study require pre-treatment fast blood sample another sample 3 month start hormone therapy .</brief_summary>
	<brief_title>Sex Hormones Blood PCSK9 Levels</brief_title>
	<detailed_description>Proprotein convertase subtilisin kexin 9 ( PCSK9 ) secrete glycoprotein first demonstrate play role lipoprotein metabolism 2003 several gain-of-function single nucleotide polymorphism ( SNPs ) PCSK9 show associate autosomal dominant hypercholesterolemia ( ADH ) . Soon , loss-of-function nonsense missense SNPs PCSK9 show associate hypocholesterolemia . Much still know PCSK9 's mechanism action , substrate ( ) , regulation , factor affect function , know PCSK9 decrease LDL clearance degradation LDL receptor . We examine plasma PCSK9 serum lipid in182 normolipidemic subject ( 98 men , 84 woman ) find Spearman analysis significant correlation plasma PCSK9 total cholesterol ( TC ) , LDL-C , TC/HDL-C men woman , suggest gender difference PCSK9 regulation and/or function . Following unexpected novel excite observation , hypothesize : serum level testosterone estradiol would significantly correlate plasma PCSK9 level , testosterone 17-B estradiol replacement therapy men woman respectively would result change level plasma PCSK9 , testosterone estradiol modify effect PCSK9 serum lipid different way , explain least part , gender dichotomy PCSK9 function , significant percentage effect hormone replacement therapy lipid mediate PCSK9 function . Cohort # 1 60 hypogonadal men cohort # 2 60 postmenopausal ( hypoestrogenic ) woman testosterone estrogen replacement therapy respectively . They undergo measurement plasma PCSK9 , serum testosterone men estradiol woman TC , triglyceride , HDL-C LDL-C 3 month start replacement therapy . These panel study allow u evaluate whether ( ) hormone replacement therapy effect PCSK9 , ( b ) whether result change PCSK9 associate lipid response .</detailed_description>
	<mesh_term>Hypercholesterolemia</mesh_term>
	<mesh_term>Testosterone</mesh_term>
	<criteria>Males : 18 year age old hypogonadal males/males prostate cancer Prior clinical decision start testosterone therapy Females : 30 year age old postmenopausal woman Prior clinical decision start estrogen therapy Cognitive impairment , active chronic hepatic renal disease , diagnose diabetes mellitus , alcohol consumption great 4 drinks/day receive need progestogen therapy woman</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2010</verification_date>
	<keyword>PCSK9</keyword>
	<keyword>Lipoprotein metabolism</keyword>
	<keyword>testosterone</keyword>
	<keyword>estradiol</keyword>
</DOC>